<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04137302</url>
  </required_header>
  <id_info>
    <org_study_id>CHRO 2019-04</org_study_id>
    <nct_id>NCT04137302</nct_id>
  </id_info>
  <brief_title>Administration of Hydrocortisone in Young Healthy Male Volunteers</brief_title>
  <acronym>H-CORT</acronym>
  <official_title>Administration of Hydrocortisone in Young Healthy Male Volunteers: Determination of Biomarkers for Distinguishing Between Local and Systemic Pathways</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional d'Orléans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French Anti-Doping Agency (AFLD)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Régional d'Orléans</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The misuse of cortisone or hydrocortisone for doping purpose in sport has been widely
      reported in the literature, but to date, no formal testing procedure is available and
      applicable in an anti-doping laboratory to detect hydrocortisone doping abuse , i.e.,
      administration by systemic way.

      The investigators therefore propose to identify biomarkers that clearly distinguish between
      an authorized local administration of hydrocortisone and a prohibited systemic
      administration, by studying the impact of 5-day administration of hydrocortisone per 2
      different routes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical research with two groups of ten volunteers one group with 5 days with local
      administration (cream, applied to healthy skin) one group with 5 days with systemic route of
      administration (per os)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2019</start_date>
  <completion_date type="Anticipated">July 13, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 13, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Monocentric, randomized, open-label study
Distribution of patients in groups according to a ratio (1:1)</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary concentration of cortisol and its metabolites with Gas Chromatography Mass Spectrometry</measure>
    <time_frame>7 days</time_frame>
    <description>Gas Chromatography Mass Spectrometry to study biomarkers urine level at 8 am, 10 am, 8 pm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary concentration of cortisol and its metabolites with Gas Chromatography Mass Spectrometry</measure>
    <time_frame>Day 12</time_frame>
    <description>Gas Chromatography Mass Spectrometry to study biomarkers urine level at 8 am,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary concentration of cortisol and its metabolites with Isotope ratio mass spectrometry t</measure>
    <time_frame>7 days</time_frame>
    <description>Isotope ratio mass spectrometry to study biomarkers urine level at 8 am, 10 am, 8 pm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary concentration of cortisol and its metabolites with Isotope ratio mass spectrometry t</measure>
    <time_frame>Day 12</time_frame>
    <description>Isotope ratio mass spectrometry to study biomarkers urine level at 8 am</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood concentration of cortisol</measure>
    <time_frame>7 days</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay) to study cortisol concentration at 8 am; 10 am, 8 pm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentration of cortisol</measure>
    <time_frame>Day 12</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay) to study cortisol concentration at 8 am;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentration of DeHydroEpiAndrostérone</measure>
    <time_frame>7 days</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay) to study cortisol concentration at 8 am; 10 am, 8 pm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentration of DeHydroEpiAndrostérone</measure>
    <time_frame>day 12</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay) to study cortisol concentration at 8 am;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentration of Adreno CorticoTrophic Hormone</measure>
    <time_frame>7 days</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay) to study cortisol concentration at 8 am; 10 am, 8 pm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentration of Adreno CorticoTrophic Hormone</measure>
    <time_frame>Day 12</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay) to study cortisol concentration at 8 am;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>saliva concentration of cortisol</measure>
    <time_frame>7 days</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay, ) to study cortisol concentration at 8 am; 10 am, 8 pm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>saliva concentration of DeHydroEpiAndrostérone</measure>
    <time_frame>7 days</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay, ) to study cortisol concentration at 8 am; 10 am, 8 pm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>saliva concentration of Adreno CorticoTrophic Hormone</measure>
    <time_frame>7 days</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay, ) to study cortisol concentration at 8 am; 10 am, 8 pm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>saliva concentration of cortisol</measure>
    <time_frame>Day 12</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay) to study cortisol concentration at 8 am</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>saliva concentration of Adreno CorticoTrophic Hormone</measure>
    <time_frame>Day 12</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay) to study cortisol concentration at 8 am</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>saliva concentration of DeHydroEpiAndrostérone</measure>
    <time_frame>Day 12</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay) to study cortisol concentration at 8 am</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Anti-doping Campaign, Detection of Hydrocortisone</condition>
  <arm_group>
    <arm_group_label>Topical hydrocortisone administration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dermal cream (twice a day, 2.5 g of cream, 1% hydrocortisone during 5 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Systemic hydrocortisone administration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tablets (once a day, 50 mg, morning, during 50 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone administration</intervention_name>
    <description>Hydrocortisone administration with collection of blood, urine and saliva samples before (1 week), during (5 days) and after (1 week) the 2 treatments</description>
    <arm_group_label>Systemic hydrocortisone administration</arm_group_label>
    <arm_group_label>Topical hydrocortisone administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male subjects

               -  aged 18 to 30 years

               -  18 &lt; BMI &lt; 28

               -  participating in regular physical activity (3-5 times/week)

               -  subjects not on medication

        Exclusion Criteria:

        asthmatic subjects or history of respiratory or cardiac pathology; use of corticosteroids
        in the past 6 months; high blood pressure; ulcerated lesions of the skin, acne, rosacea;
        Infectious state (bacterial, viral, and fungal infections); diabetic subjects; ulcerative
        history and other gastrointestinal disorders; lactose allergy; galactose intolerance;
        ulcerative colonic pathology; myastenia gravis; live vaccine kidney failure
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AMIOT Virgile, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Regional Center of ORLEANS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DESPUJOLS Aurélie</last_name>
    <phone>33238744071</phone>
    <email>aurelie.despujols@chr-orleans.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>BUISSON Corinne, PhD</last_name>
    <phone>33146602869</phone>
    <email>c.buisson@afld.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Regional Hospital Center of ORLEANS</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virgile AMIOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Virgile AMIOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Arlettaz A, Portier H, Lecoq AM, Rieth N, De Ceaurriz J, Collomp K. Effects of short-term prednisolone intake during submaximal exercise. Med Sci Sports Exerc. 2007 Sep;39(9):1672-8.</citation>
    <PMID>17805102</PMID>
  </reference>
  <reference>
    <citation>Buisson C, Mongongu C, Frelat C, Jean-Baptiste M, de Ceaurriz J. Isotope ratio mass spectrometry analysis of the oxidation products of the main and minor metabolites of hydrocortisone and cortisone for antidoping controls. Steroids. 2009 Mar;74(3):393-7. doi: 10.1016/j.steroids.2008.11.001. Epub 2008 Nov 13.</citation>
    <PMID>19056411</PMID>
  </reference>
  <reference>
    <citation>Collomp K, Arlettaz A, Buisson C, Lecoq AM, Mongongu C. Glucocorticoid administration in athletes: Performance, metabolism and detection. Steroids. 2016 Nov;115:193-202. doi: 10.1016/j.steroids.2016.09.008. Epub 2016 Sep 16. Review.</citation>
    <PMID>27643452</PMID>
  </reference>
  <reference>
    <citation>Collomp K, Arlettaz A, Portier H, Lecoq AM, Le Panse B, Rieth N, De Ceaurriz J. Short-term glucocorticoid intake combined with intense training on performance and hormonal responses. Br J Sports Med. 2008 Dec;42(12):983-8. Epub 2007 Nov 29.</citation>
    <PMID>18048433</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 22, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2019</study_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hydrocortisone (cortisol)</keyword>
  <keyword>local administration of cortisol</keyword>
  <keyword>systemic administration of cortisol</keyword>
  <keyword>biomarkers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

